Vorinostat.
Grant
Steven
S
Easley
Chris
C
Kirkpatrick
Peter
P
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017277:Drug Approval; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration; D000077337:Vorinostat
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D000077337:Vorinostat